Q-omics provides the consensus-scored HNRNPA1P67 profile across patient tissues and cancer cell-line models. HNRNPA1P67 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, HNRNPA1P67 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, HNRNPA1P67 RNA expression shows 11,056 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight CESC, COAD, and ACC as cancer lineages where HNRNPA1P67 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPA1P67 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPA1P67 survival associations across molecular data types. HNRNPA1P67 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPA1P67 RNA expression–survival associations across cancer types. High HNRNPA1P67 expression shows unfavorable associations in STAD, but favorable associations in CESC, UCS, LUSC, THCA and KIRC. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for HNRNPA1P67 RNA expression.
This table summarizes HNRNPA1P67 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for HNRNPA1P67. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPA1P67 shows lower tumor expression in UCEC and higher tumor expression in COAD, LUSC, KIRC, LIHC and READ. The COAD box plot shows higher HNRNPA1P67 RNA expression in tumor versus normal tissue (log2 FC = +0.263, t-test p < 0.001).
This table shows molecular features associated with HNRNPA1P67 in patient tissues and cancer cell lines. In patient samples, HNRNPA1P67 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
